In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
Children and adolescents trials
In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]
In September, KCONVAC started phase II trials with 480 participants in China.[5]
Authorizations
Graphs are unavailable due to technical issues. There is more info on
Phabricator and on
MediaWiki.org.
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]
References
^Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at
ClinicalTrials.gov
^Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at
ClinicalTrials.gov
^Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at
ClinicalTrials.gov
^Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at
ClinicalTrials.gov
^Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at
ClinicalTrials.gov